A Randomized, Multi-Center, Phase 2 Study to Evaluate Safety and Efficacy of Subcutaneous Injections of RG-101 in Combination with Oral Agents in Treatment Naïve, Genotype 1 and 4, Chronic Hepatitis C Patients

Trial Profile

A Randomized, Multi-Center, Phase 2 Study to Evaluate Safety and Efficacy of Subcutaneous Injections of RG-101 in Combination with Oral Agents in Treatment Naïve, Genotype 1 and 4, Chronic Hepatitis C Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs RG 101 (Primary) ; Daclatasvir; Ledipasvir/sofosbuvir; Simeprevir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Regulus Therapeutics
  • Most Recent Events

    • 02 Mar 2017 Top-line results published in the Regulus Therapeutics media release.
    • 02 Mar 2017 Status changed from active, no longer recruiting to completed, according to Regulus Therapeutics media release.
    • 23 Feb 2017 This trial is completed in Hungary (end date: 2017-01-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top